Every 8-K that Pasithea Therapeutics Corp. (KTTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KTTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KTTA filings page.
Pasithea Therapeutics Corp. (KTTA) reported the results of its September 9, 2026 Annual Meeting of Stockholders. Stockholders voted on electing two Class III directors, ratifying the independent auditor, and authorizing a potential reverse stock split.
Of 33,414,448 common shares outstanding and entitled to vote, 26,142,328 were represented, constituting a quorum. Tiago Reis Marques and Lawrence Steinman were elected as Class III directors by plurality. Stockholders ratified the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026. Stockholders also approved an amendment to the certificate of incorporation that permits the Board, in its discretion, to implement a reverse stock split of issued common shares at a ratio between 1-for-2 and 1-for-20 at any time up to one year after the Annual Meeting.
Pasithea Therapeutics Corp. (KTTA) reports that Nasdaq has granted an additional 180-day period, until February 16, 2027, to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing. The initial 180-day grace period had been set to expire on August 19, 2026. The company states it will continue monitoring its share price and may consider actions such as a reverse stock split to regain compliance. If compliance is not achieved within the extended period, Nasdaq may initiate delisting proceedings, which Pasithea would have the right to appeal.
Pasithea Therapeutics Corp. appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026. He will lead clinical development and medical strategy as the company advances its PAS-004 MEK inhibitor program in neurofibromatosis type 1 and other indications.
Under an Executive Employment Agreement dated April 3, 2026, Dr. Krishnan receives an initial $500,000 base salary and is eligible for an annual discretionary bonus of up to 40% of salary, plus participation in benefit plans. On May 1, 2026, the board granted him options to purchase 1,129,323 shares at an exercise price of $0.841 per share, alongside sizable option grants to the CEO, CFO, other employees and non‑employee directors, with multi‑year vesting and full vesting upon a Change in Control.
Pasithea Therapeutics Corp. received a notice from Nasdaq on February 20, 2026 stating that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The company has 180 calendar days, until August 19, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least ten consecutive business days. If it meets other listing standards, it may qualify for an additional 180-day period and could use actions such as a reverse stock split to cure the deficiency.
If compliance is not regained, Nasdaq staff may move to delist the shares, though the company would have the right to appeal. The company plans to monitor its share price and evaluate options, and states that this notice does not affect its business operations or SEC reporting.
Pasithea Therapeutics Corp. held a special stockholder meeting where investors approved two major share-related changes. Stockholders first approved a certificate amendment increasing authorized common stock from 100,000,000 to 500,000,000 shares, expanding the company’s capacity to issue new equity in the future.
They also approved an amendment to the 2023 Stock Incentive Plan, raising the shares authorized for issuance under the plan by 11,985,779 shares to a new total of 14,000,000 shares. Of 23,091,062 shares outstanding and entitled to vote, 16,746,261 were represented, and both proposals passed by majority vote.
Pasithea Therapeutics Corp. has regained compliance with Nasdaq’s minimum $1.00 bid price requirement for its common stock.
The company had previously received a notice on June 23, 2025 that its shares were below the $1.00 minimum bid price set by Nasdaq Listing Rule 5550(a)(2) and was given until December 22, 2025 to cure the deficiency. On December 12, 2025, Nasdaq informed Pasithea that the stock had maintained a closing bid at or above $1.00 per share for a sufficient number of consecutive business days and confirmed that the matter is now closed.
Pasithea Therapeutics Corp. (KTTA) filed an 8-K to highlight a series of November press releases focused on its experimental drug PAS-004. The company reported positive interim Phase 1 data from its first-in-human trial in patients with advanced solid tumors driven by MAPK pathway alterations, including those with RAS, NF1 or RAF mutations or who have failed prior BRAF/MEK inhibition.
Pasithea also announced positive tablet pharmacokinetic (PK) data for PAS-004 in a Phase 1/1b study in adults with NF1-associated plexiform neurofibromas, and additional positive safety, PK and pharmacodynamic (PD) data from Cohort 7 (37mg capsule) in its ongoing first-in-human cancer trial. Separately, the ALS Association awarded an approximately $1 million Hoffman ALS Clinical Trial Award grant to study the efficacy, safety and tolerability of PAS-004 in ALS patients.
Pasithea Therapeutics (KTTA) announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham for its Phase 1/1b open-label study of PAS-004 in adults with neurofibromatosis type 1. Enrollment at the UAB site is expected to begin immediately. The company also said it will serve as Platinum Sponsor of the 2025 NF Caregivers Symposium hosted at UAB on November 8, 2025.
Pasithea Therapeutics (KTTA) updated executive and director compensation. The Board raised the CEO’s base salary to $533,000 and set his target bonus at 55% of base pay. The CFO’s base salary increased to $391,000 with a 40% target bonus. These cash changes are retroactive to January 1, 2025.
Equity awards were granted at an exercise price of $0.715 per share as of October 24, 2025: the CEO received options for 493,341 shares, the CFO 317,266 shares, and certain employees an aggregate of 352,266 shares. Each vests 33% on the one‑year anniversary, then quarterly over the next two years, and fully upon a Change in Control.
Director pay was adjusted to conserve cash: the Audit Chair retainer increased by $5,000 to $15,000, while the Board Chair’s annual cash compensation was reduced from $100,000 to $35,000 effective October 1, 2025. Each non‑employee director received options for 42,913 shares at $0.715, vesting in full after one year, with Change in Control acceleration. Prof. Steinman’s consulting payments were reduced from $25,000 per quarter to $1.00 per quarter effective October 1, 2025, and he received a one‑time option for 200,000 shares at $0.715, vesting after one year.
Pasithea Therapeutics Corp. reported progress in its Phase 1/1b study of PAS-004 in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. The company has activated two clinical trial sites in South Korea, Asan Medical Centre and Severance Hospital Yonsei University Health System, which are now recruiting, and the first South Korean patient has been dosed.
Globally, the NF1 trial has moved from Cohort 1, a 4mg tablet dose, to enrolling patients in Cohort 2 at an 8mg tablet dose after an external Safety Review Committee recommended proceeding without modification. Initial interim clinical data from the first two cohorts are expected in the first quarter of 2026, which will begin to show how PAS-004 is performing on safety, tolerability, pharmacokinetics and pharmacodynamics in this NF1 population.